Neil Woodford, manager of the £6.6bn Woodford Equity Income fund, has significantly reduced exposure to former top holding AstraZeneca in order to invest in areas where he feels valuations are more attractive, such as domestic names.
Exposure to the pharmaceutical company has been gradually reduced over the past 12 months, moving from being its top holding representing 8% of the portfolio in April 2017 to just 1%, now making it the...
European Commission relents to pressure
Latest news and analysis
Remains open to existing investors
Chairs first meeting this afternoon
Effective from 1 December